A study published online October 8, 2026, in Veterinary Microbiology reports that the host protein CASTOR2 restricts internalization of porcine reproductive and respiratory syndrome virus (PRRSV) by acting on the AKT–mTOR signaling pathway and by interacting with the viral glycoprotein GP5.

Authors Yuchao Yan, Changyan Li, Xin Ma, Yinhao Zhang, Junyang Zhang, Xinyi Zhang, Qinye Song, and Jinhai Huang conducted the work, which positions CASTOR2 as a component of the host's antiviral response against one of the most costly pathogens in swine production.

What does the finding change at the barn level?

PRRSV remains a drivers of reproductive failure in sows and respiratory disease in growing pigs. The new paper does not describe a vaccine, drug, or field intervention. Its value is mechanistic: it identifies a specific host protein, CASTOR2, as a restriction factor that acts early in the viral life cycle.

Two mechanisms emerge from the study's title framing:

• CASTOR2 restricts PRRSV internalization — the step at which the virus enters the cell, before replication begins.

• The effect runs through the AKT–mTOR signaling axis, a central pathway governing cell growth and metabolism that viruses frequently exploit.

• Separately, CASTOR2 interacts with viral glycoprotein GP5, a structural protein known to mediate viral attachment and entry.

Together, these results give researchers two concrete entry points — a host pathway and a viral protein — for future antiviral or breeding-resistance strategies.

Why the GP5 interaction matters

GP5 sits on the viral envelope and plays a role in receptor engagement. A host protein that physically binds GP5 and limits internalization offers a defined molecular target. For research teams working on PRRSV entry inhibitors or on pigs engineered for enhanced resistance, a named host–virus protein interaction narrows the search space considerably compared with broader screens.

The AKT–mTOR finding adds a second layer. This pathway regulates translation and cell metabolism, and the study links its modulation by CASTOR2 to reduced viral uptake. That connection suggests PRRSV internalization depends, at least in part, on the metabolic state of the host cell — a hypothesis the authors' data now support at the level of a single restriction factor.

What the study does not claim

The paper, appearing in Veterinary Microbiology, is a mechanistic virology study rather than a clinical trial. It reports no field efficacy data, no vaccine claims, and no regulatory submissions to FDA CVM, EMA, or USDA — none are implicated by this basic-science finding. Producers and practitioners should read it as groundwork: a candidate pathway and protein pair that downstream product development could target.

For companion-animal and public-health audiences, the implications are indirect. PRRSV is not a zoonotic pathogen, so the public-health relevance is limited to the general advance in understanding how AKT–mTOR signaling shapes viral entry — a mechanism studied across multiple virus families.

Forward look

With CASTOR2 now established as a PRRSV restriction factor acting through AKT–mTOR signaling and GP5 binding, the next research steps — antiviral screening against this axis and evaluation in porcine models — will determine whether the mechanism can move from cell-culture insight to a practical tool against a disease that continues to cost the swine industry billions annually.